{"id":76547,"date":"2026-08-25T16:15:20","date_gmt":"2026-08-25T08:15:20","guid":{"rendered":"https:\/\/flcube.com\/?p=76547"},"modified":"2026-08-25T16:15:21","modified_gmt":"2026-08-25T08:15:21","slug":"wuxi-xdc-h1-revenue-surges-41-5-to-rmb-3-7-billion-as-adc-backlog-jumps-50-4","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76547","title":{"rendered":"WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>WuXi XDC<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2268:HKG\">HKG: 2268<\/a>) reported <strong>interim results for the first half of 2026<\/strong> on Aug. 24, with total revenue reaching <strong>RMB 3.701 billion<\/strong>, up <strong>41.5% year\u2011on\u2011year at constant exchange rates (CER)<\/strong>. Adjusted net profit attributable to parent company shareholders grew <strong>37.4% YoY to RMB 1.027 billion<\/strong>, as the company cemented its position as a leading <strong>ADC CRDMO<\/strong> service provider.<\/p>\n\n\n\n<h2 id=\"h-h1-2026-financial-highlights\" class=\"wp-block-heading\">H1 2026 Financial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>2026 H1<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>RMB 3.701 billion<\/td><td><strong>+41.5% (CER)<\/strong><\/td><\/tr><tr><td><strong>Adjusted Net Profit (attributable)<\/strong><\/td><td>RMB 1.027 billion<\/td><td><strong>+37.4%<\/strong><\/td><\/tr><tr><td><strong>Service Order Backlog<\/strong><\/td><td>~USD 2.0 billion<\/td><td><strong>+50.4%<\/strong><\/td><\/tr><tr><td><strong>Total Order Backlog (incl. potential milestones)<\/strong><\/td><td>~USD 2.2 billion<\/td><td><strong>+62.2%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-growth-drivers\" class=\"wp-block-heading\">Growth Drivers<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Market Tailwind:<\/strong> Revenue growth was primarily driven by the <strong>continued active development of the global ADC and broader bioconjugate market<\/strong>, alongside the Group&#8217;s strengthened market share as a leading ADC CRDMO provider.<\/li>\n\n\n\n<li><strong>Customer Base Expansion:<\/strong> The cumulative customer base <strong>exceeded 810<\/strong>, with <strong>15 of the world&#8217;s top 20 multinational pharmaceutical companies<\/strong> now in collaboration with the Group.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-operational-metrics-record-first-half\" class=\"wp-block-heading\">Operational Metrics \u2013 Record First Half<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026 H1<\/th><\/tr><\/thead><tbody><tr><td><strong>Integrated CMC (iCMC) Projects<\/strong><\/td><td>328 total<\/td><\/tr><tr><td><strong>New Projects Signed in H1<\/strong><\/td><td>51 (historical high)<\/td><\/tr><tr><td><strong>Integrated ADC Projects<\/strong><\/td><td>286<\/td><\/tr><tr><td><strong>Integrated XDC Projects<\/strong><\/td><td>42 (increased)<\/td><\/tr><tr><td><strong>Cumulative Customers<\/strong><\/td><td>810+<\/td><\/tr><tr><td><strong>Top\u201120 Pharma Collaborations<\/strong><\/td><td>15 of 20<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>51 new iCMC projects signed<\/strong> in the first half set a <strong>new historical high<\/strong>, underscoring accelerating demand for WuXi XDC&#8217;s integrated development and manufacturing capabilities.<\/p>\n\n\n\n<h2 id=\"h-strategic-outlook\" class=\"wp-block-heading\">Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Backlog Visibility:<\/strong> With an outstanding service order backlog of approximately <strong>USD 2.0 billion (+50.4% YoY)<\/strong> \u2014 rising to roughly <strong>USD 2.2 billion (+62.2% YoY)<\/strong> including potential milestone payments \u2014 WuXi XDC enters the second half with strong revenue visibility.<\/li>\n\n\n\n<li><strong>Bioconjugate Super\u2011Cycle:<\/strong> As ADCs continue to dominate oncology deal\u2011making and clinical pipelines globally, contract development and manufacturing organizations with end\u2011to\u2011end bioconjugate capabilities remain among the sector&#8217;s key beneficiaries.<\/li>\n\n\n\n<li><strong>Platform Diversification:<\/strong> The growth of integrated <strong>XDC projects to 42<\/strong> signals rising traction beyond classic ADCs, as next\u2011generation conjugate modalities broaden WuXi XDC&#8217;s addressable market.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding WuXi XDC&#8217;s revenue growth, order backlog and market outlook. Actual results may differ due to risks including project execution, customer spending, exchange rate movements and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082401213.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082401213.\"><\/object><a id=\"wp-block-file--media-9f1c3ac2-3cad-477a-9dcb-52938143df3a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082401213.pdf\">2026082401213<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082401213.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9f1c3ac2-3cad-477a-9dcb-52938143df3a\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082401221.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082401221.\"><\/object><a id=\"wp-block-file--media-59be8822-8689-4734-a149-250f1929d7af\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082401221.pdf\">2026082401221<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082401221.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-59be8822-8689-4734-a149-250f1929d7af\"><\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WuXi XDC (HKG: 2268) reported interim results for the first half of 2026 on Aug&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":76550,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[19,27],"class_list":["post-76547","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-cro-cmo-cdmo","tag-finanical-reports"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4% - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"WuXi XDC (HKG: 2268) reported interim results for the first half of 2026 on Aug. 24, with total revenue reaching RMB 3.701 billion, up 41.5% year\u2011on\u2011year at constant exchange rates (CER). Adjusted net profit attributable to parent company shareholders grew 37.4% YoY to RMB 1.027 billion, as the company cemented its position as a leading ADC CRDMO service provider.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76547\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%\" \/>\n<meta property=\"og:description\" content=\"WuXi XDC (HKG: 2268) reported interim results for the first half of 2026 on Aug. 24, with total revenue reaching RMB 3.701 billion, up 41.5% year\u2011on\u2011year at constant exchange rates (CER). Adjusted net profit attributable to parent company shareholders grew 37.4% YoY to RMB 1.027 billion, as the company cemented its position as a leading ADC CRDMO service provider.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76547\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-25T08:15:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-25T08:15:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2503.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76547#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76547\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%\",\"datePublished\":\"2026-08-25T08:15:20+00:00\",\"dateModified\":\"2026-08-25T08:15:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76547\"},\"wordCount\":351,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76547#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2503.webp\",\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"Finanical Reports\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76547#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76547\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76547\",\"name\":\"WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4% - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76547#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76547#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2503.webp\",\"datePublished\":\"2026-08-25T08:15:20+00:00\",\"dateModified\":\"2026-08-25T08:15:21+00:00\",\"description\":\"WuXi XDC (HKG: 2268) reported interim results for the first half of 2026 on Aug. 24, with total revenue reaching RMB 3.701 billion, up 41.5% year\u2011on\u2011year at constant exchange rates (CER). Adjusted net profit attributable to parent company shareholders grew 37.4% YoY to RMB 1.027 billion, as the company cemented its position as a leading ADC CRDMO service provider.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76547#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76547\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76547#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2503.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2503.webp\",\"width\":1080,\"height\":608,\"caption\":\"WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76547#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4% - Insight, China&#039;s Pharmaceutical Industry","description":"WuXi XDC (HKG: 2268) reported interim results for the first half of 2026 on Aug. 24, with total revenue reaching RMB 3.701 billion, up 41.5% year\u2011on\u2011year at constant exchange rates (CER). Adjusted net profit attributable to parent company shareholders grew 37.4% YoY to RMB 1.027 billion, as the company cemented its position as a leading ADC CRDMO service provider.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76547","og_locale":"en_US","og_type":"article","og_title":"WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%","og_description":"WuXi XDC (HKG: 2268) reported interim results for the first half of 2026 on Aug. 24, with total revenue reaching RMB 3.701 billion, up 41.5% year\u2011on\u2011year at constant exchange rates (CER). Adjusted net profit attributable to parent company shareholders grew 37.4% YoY to RMB 1.027 billion, as the company cemented its position as a leading ADC CRDMO service provider.","og_url":"https:\/\/flcube.com\/?p=76547","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-25T08:15:20+00:00","article_modified_time":"2026-08-25T08:15:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2503.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76547#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76547"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%","datePublished":"2026-08-25T08:15:20+00:00","dateModified":"2026-08-25T08:15:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76547"},"wordCount":351,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=76547#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2503.webp","keywords":["CRO \/ CMO \/ CDMO","Finanical Reports"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76547#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76547","url":"https:\/\/flcube.com\/?p=76547","name":"WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4% - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=76547#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=76547#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2503.webp","datePublished":"2026-08-25T08:15:20+00:00","dateModified":"2026-08-25T08:15:21+00:00","description":"WuXi XDC (HKG: 2268) reported interim results for the first half of 2026 on Aug. 24, with total revenue reaching RMB 3.701 billion, up 41.5% year\u2011on\u2011year at constant exchange rates (CER). Adjusted net profit attributable to parent company shareholders grew 37.4% YoY to RMB 1.027 billion, as the company cemented its position as a leading ADC CRDMO service provider.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76547#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76547"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=76547#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2503.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2503.webp","width":1080,"height":608,"caption":"WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76547#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2503.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76547"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76547\/revisions"}],"predecessor-version":[{"id":76551,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76547\/revisions\/76551"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/76550"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}